545 related articles for article (PubMed ID: 33260960)
1. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
Morè S; Petrucci MT; Corvatta L; Fazio F; Offidani M; Olivieri A
Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33260960
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
4. Isatuximab: A Review of Its Use in Multiple Myeloma.
Frampton JE
Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
6. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
Chim CS; Kumar SK; Orlowski RZ; Cook G; Richardson PG; Gertz MA; Giralt S; Mateos MV; Leleu X; Anderson KC
Leukemia; 2018 Feb; 32(2):252-262. PubMed ID: 29257139
[TBL] [Abstract][Full Text] [Related]
7. Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma.
Shah B; Gray J; Abraham I; Chang M
J Oncol Pharm Pract; 2023 Jan; 29(1):170-182. PubMed ID: 35726199
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
9. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
10. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
12. Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.
Shen F; Shen W
Technol Cancer Res Treat; 2022; 21():15330338221106563. PubMed ID: 35903924
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Chen H; Chen H; Zhou Y; Xu W; Yu J; Xu Y; Zhou F
Hematology; 2023 Dec; 28(1):2225342. PubMed ID: 37343159
[TBL] [Abstract][Full Text] [Related]
14. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
Nishimura N; Terui Y; Hatake K
Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
16. Therapeutic antibodies for multiple myeloma.
Ishida T
Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.
Fazio F; Franceschini L; Tomarchio V; Rago A; Garzia MG; Cupelli L; Bongarzoni V; Andriani A; Gumenyuk S; Tafuri A; Siniscalchi A; Piciocchi A; De Fabritiis P; De Rosa L; Caravita di Toritto T; Annibali O; Cantonetti M; Petrucci MT
EJHaem; 2022 Feb; 3(1):121-128. PubMed ID: 35846211
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
20. Emerging antibodies for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]